EndoStim last week reported raising more than $12 million for its neurostimulation device for treating gastroesophageal reflux disease. The Dallas-based company hopes to bring in a total of $25 million in the round, which follows a $25 million Series D financing in May 2016. The most recent equity and options funding involved 20 unnamed investors, according to a […]
EndoStim
7 medtech stories we missed this week: June 23, 2017
From Guardant suing Foundation Medicine to Interson receiving 510(k) clearance for ultrasound probes, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Guardant levels false advertising suit against Foundation Medicine Guardant Health announced in a June 22 press release that it has filed a lawsuit against Foundation Medicine […]
Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim | Personnel Moves May 20, 2016
Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim chief exec Skyline Medical said earlier this month that prez and CEO Joshua Kornberg has stepped away from his roles at the company, and is being replaced by Carl Schwartz who will serve as interim chief executive. Prior to his time at Skyline, Schwartz served […]
EndoStim raises $25m Series D for neurostim GERD device
Five months after spiking its plans for an initial public offering, EndoStim said today that it raised a $25 million Series D round for the neurostimulation device it’s developing to treat gastroesophageal reflux disease. Saint Louis- and Nijmegen, Holland-based EndoStim said Endeavour Vision led the round, joined by existing backer Santé Ventures and new investors Wellington Partners and Gimv. Endostim […]
EndoStim officially spikes $35m IPO
EndoStim today officially spiked an initial public offering it hoped would raise $35 million for its neurostimulation device for gastroesophageal reflux disease. EndoStim, which had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system, tabled the offering in October 2014. Today the company filed a formal […]
Report: EndoStim tables IPO
EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.
EndoStim had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system.
EndoStim targets $36m IPO
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.
Topera details $25M Series C round | Wall Street Beat
Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.
EndoStim takes funding round to $11M | Wall Street Beat
EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.
St. Jude Medical seesaws on FDA warning letter
A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company’s stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
EndoStim touts European win for “ideal therapy” for acid reflux
Netherlands-based device maker EndoStim B.V. won European regulatory approval for its LES Stimulation system, an implantable muscle stimulation device for patients with severe gastro-esophageal reflux disease.
The LES system won CE Mark approval for based on clinical results form a 12-month clinical trial during which 100% of the patients were able to stop their daily drug regimen for managing their disease, according to a press release.
